157 related articles for article (PubMed ID: 8048432)
1. The use of Health Care Financing Administration data for the development of a quality improvement project on the treatment of anemia.
Eggers PW; Greer J; Jencks S
Am J Kidney Dis; 1994 Aug; 24(2):247-54. PubMed ID: 8048432
[TBL] [Abstract][Full Text] [Related]
2. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
[TBL] [Abstract][Full Text] [Related]
3. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
Powe NR; Griffiths RI; Anderson GF; de Lissovoy G; Watson AJ; Greer JW; Herbert RJ; Whelton PK
Am J Kidney Dis; 1993 Oct; 22(4):557-67. PubMed ID: 8213796
[TBL] [Abstract][Full Text] [Related]
4. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
5. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
Powe NR; Griffiths RI; Bass EB
J Am Soc Nephrol; 1993 Apr; 3(10):1660-71. PubMed ID: 8318682
[TBL] [Abstract][Full Text] [Related]
6. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
7. Medicare program; coverage of epoetin (EPO) used by competent home dialysis patients--HCFA. Final rule.
Fed Regist; 1994 Jan; 59(6):1278-85. PubMed ID: 10133081
[TBL] [Abstract][Full Text] [Related]
8. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
[TBL] [Abstract][Full Text] [Related]
9. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
[TBL] [Abstract][Full Text] [Related]
10. Health care policies/economics of the geriatric renal population.
Eggers PW
Am J Kidney Dis; 1990 Oct; 16(4):384-91. PubMed ID: 2121023
[TBL] [Abstract][Full Text] [Related]
11. Implications of Medicare Part D in CKD anemia treatment.
Stefanacci RG
J Am Med Dir Assoc; 2006 Nov; 7(9 Suppl):S13-6; quiz S17-21. PubMed ID: 17098632
[TBL] [Abstract][Full Text] [Related]
12. Quality improvement activity directed at the national level: examples from the Health Care Financing Administration.
Frankenfield DL; Marciniak TA; Drass JA; Jencks S
Qual Manag Health Care; 1997; 5(4):12-8. PubMed ID: 10169781
[TBL] [Abstract][Full Text] [Related]
13. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
14. Improving clinical processes: one dialysis facility's experiences.
Bennett J; Cranford W; Staples B; Hartline P; Blondin J; Harter H; Rutherford WE
Qual Manag Health Care; 1997; 6(1):45-60. PubMed ID: 10176408
[TBL] [Abstract][Full Text] [Related]
15. The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy.
Cotter D; Thamer M; Zhang Y
Nephrol News Issues; 2011 Aug; 25(9):15-6, 18. PubMed ID: 21905526
[No Abstract] [Full Text] [Related]
16. A review of the first year of Medicare coverage of erythropoietin.
Griffiths RI; Powe NR; Greer J; de Lissovoy G; Anderson GF; Whelton PK; Watson AJ; Eggers PW
Health Care Financ Rev; 1994; 15(3):83-102. PubMed ID: 10137799
[TBL] [Abstract][Full Text] [Related]
17. Recombinant erythropoietin and Medicare payment.
Sisk JE; Gianfrancesco FD; Coster JM
JAMA; 1991 Jul; 266(2):247-52. PubMed ID: 2056627
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
Messana T
Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
[TBL] [Abstract][Full Text] [Related]
19. Implementing the Health Care Quality Improvement Program in the Medicare ESRD Program: a new era of quality improvement in ESRD.
McClellan WM; Helgerson SD; Frederick PR; Wish JB; McMullan M
Adv Ren Replace Ther; 1995 Apr; 2(2):89-94. PubMed ID: 7614353
[TBL] [Abstract][Full Text] [Related]
20. Medicare Program; End-Stage Renal Disease Prospective Payment System, Coverage and Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program Bid Surety Bonds, State Licensure and Appeals Process for Breach of Contract Actions, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program and Fee Schedule Adjustments, Access to Care Issues for Durable Medical Equipment; and the Comprehensive End-Stage Renal Disease Care Model. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2016 Nov; 81(214):77834-969. PubMed ID: 27905888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
